Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.65% | 52.56% | 164.97% | 261.85% | 235.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.57% | 24.33% | 83.94% | 104.30% | 85.70% |
| Operating Income | -22.57% | -24.33% | -83.94% | -104.30% | -85.70% |
| Income Before Tax | -20.12% | -22.79% | -86.82% | -100.53% | -74.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.12% | -22.79% | -86.82% | -100.53% | -74.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.12% | -22.79% | -86.82% | -100.53% | -74.32% |
| EBIT | -22.57% | -24.33% | -83.94% | -104.30% | -85.70% |
| EBITDA | -22.63% | -24.44% | -84.37% | -104.91% | -86.13% |
| EPS Basic | 5.18% | 6.75% | -24.37% | 67.19% | 83.16% |
| Normalized Basic EPS | 7.07% | 8.65% | -21.44% | 66.56% | 81.98% |
| EPS Diluted | 5.18% | 6.75% | -24.37% | 67.19% | 83.16% |
| Normalized Diluted EPS | 7.07% | 8.65% | -21.44% | 66.56% | 81.98% |
| Average Basic Shares Outstanding | 28.59% | 37.41% | 53.09% | 112.60% | 196.66% |
| Average Diluted Shares Outstanding | 28.59% | 37.41% | 53.09% | 112.60% | 196.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |